Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of SARS-CoV-2 Variant Vaccines
NCT05289037Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, tozinameran, BNT162b2 bivalent (wildtype and Omicron BA.1) in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2022; status: completed.
02
Drugs
mRNA-1273.351mRNA-1273.529mRNA-1273.617.2tozinameranBNT162b2 bivalent (wildtype and Omicron BA.1)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05289037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289037.